Duchenne Muscular Dystrophy: A Practice Update

Review Article

Abstract

Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder caused by a deficient or defective synthesis of dystrophin protein. DMD is the most common form of muscular dystrophy with an incidence of about 1 in 5000 live boys. Though primarily resulting in progressive muscle weakness, it affects various other organs as well. Heart, brain and smooth muscles are commonly involved, because of expression of dystrophin in these organs. The management of DMD requires a multidisciplinary liaison, anticipatory management and prevention of the complications. Consensus based international recommendation for management of DMD have been published in the year 2010, recognizing DMD as a multi-systemic and progressive disease. The proper management of a boy with DMD can improve ambulation, independence, quality of life and delay disease – related complications. A lot can be done to comfort affected children and their care givers even in a resource limited setting. This review discusses these options and also the current understanding of the disease.

Keywords

Myopathy Muscle disease Rehabilitation Genetic 

References

  1. 1.
    Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.CrossRefPubMedGoogle Scholar
  2. 2.
    Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177–89.CrossRefPubMedGoogle Scholar
  3. 3.
    Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet. 2013;21:1049–53.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ferlini A, Neri M, Gualandi F. The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord. 2013;23:4–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Zubrzycka-Gaarn EE, Bulman DE, Karpati G, et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature. 1988;333:466–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Matsumura K, Campbell KP. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve. 1994;17:2–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Menke A, Jockusch H. Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature. 1991;349:69–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve. 2000;23:1456–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB. The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials. Trans Am Neurol Assoc. 1981;106:195–9.PubMedGoogle Scholar
  10. 10.
    Viswanathan V. Current concepts in dystrophinopathies. Indian J Pediatr. 2015;82:172–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Darras BT, Menache-Starobinski CC, Hinton V, Kunkel LM. Dystrophinopathies. In: Darras BT, editor. Neuromuscular disorders of infancy, childhood and adolescence: a clinicians approach. 2nd ed. London, UK: Elesevier; 2015. p. 551–92.Google Scholar
  12. 12.
    Cotton S, Voudouris NJ, Greenwood KM. Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol. 2001;43:497–501.CrossRefPubMedGoogle Scholar
  13. 13.
    Tian C, Wong BL, Hornung L, et al. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:760–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Viggiano E, Ergoli M, Picillo E, Politano L. Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy. Hum Genet. 2016;135:685–98.CrossRefPubMedGoogle Scholar
  15. 15.
    Bogue L, Peay H, Martin A, Lucas A, Ramchandren S. Knowledge of carrier status and barriers to testing among mothers of sons with Duchenne or Becker muscular dystrophy. Neuromuscul Disord. 2016;26:860–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Rosalki SB. Serum enzymes in disease of skeletal muscle. Clin Lab Med. 1989;9:767–81.PubMedGoogle Scholar
  17. 17.
    Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, et al. DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations. PLoS One. 2015;10:e0135189.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;5:CD003725.Google Scholar
  19. 19.
    Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:465–72.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pane M, Fanelli L, Mazzone ES, et al. Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test. Neuromuscul Disord. 2015;25:749–53.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  1. 1.Pediatric Neurology and Neurodevelopment Unit, Department of Pediatrics, Advanced Pediatric CentrePost Graduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations